Author:
Kindler Hedy Lee,Bylow Kathryn
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA J Clin 2006, 56:106–130.
2. Gloeckler Ries LA, Reichman ME, Lewis DR, et al.: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8:541–552.
3. Burris HA III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403–2413.
4. Friberg G, Kindler HL: Chemotherapy for advanced pancreatic cancer: past, present, and future. Curr Oncol Rep 2005, 7:186–195.
5. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] [abstract]. Proc ASCO 2005, 23(16S):1s.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献